A blood test can now flag pancreatic cancer before symptoms appear. An AI model can predict prostate cancer metastasis from a single scan. A previously unknown biomarker in extracellular vesicles can tell oncologists in real time whether a therapy is working. These aren’t lab curiosities — they carry granted patents, clinical validation data, and in some cases regulatory designations already in hand.
We traced patent filings, clinical studies, and partnerships from startups and health systems including Medicovestor, EG BioMed, Nuvance Health, Exini Diagnostics, and Tempus AI to map where oncology innovation is headed next — and which approaches are still open ground.
What’s Inside the Report?
Breakthrough Innovation – Discover how Medicovestor, EG BioMed, Nuvance Health, Exini Diagnostics, and Tempus AI are tackling cancer’s toughest diagnostic and treatment gaps, from late detection to mismatched immunotherapy response.
Innovative Technologies – Identify the latest approaches, including epigenetic biomarker panels, AI-based metastasis prediction from imaging, extracellular vesicle biomarkers, high-affinity antibody platforms, and multi-gene immune profile scoring.
Real-World Results & Applications – See how innovations like EG BioMed’s pancreatic cancer blood test and Tempus AI’s Immune Profile Score are moving from clinical studies into real-world validation and patient stratification.
Regulatory & Patent Insights – Navigate patent grant status, clinical trial phases, FDA designations, and strategic partnerships shaping which of these innovations reach patients first.
These innovations are solving late detection, treatment mismatch, and the lack of reliable biomarkers across major cancer types. Fill out the form to access our comprehensive report on breakthrough innovations in oncology!
